MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe."""@en ; dct:identifier "drugbank:DB05786" ; dct:title "MGI-114"@en ; adv:Drug ; rdfs:label "MGI-114 [drugbank:DB05786]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05786> . }